Repligen (RGEN) 46th Annual William Blair Growth Stock Conference summary
Event summary combining transcript, slides, and related documents.
46th Annual William Blair Growth Stock Conference summary
3 Jun, 2026Key strategic themes
Innovation and diversification drive growth, with a broad product portfolio and a focus on launching new solutions and technologies across bioprocessing, including fluid management, filtration, chromatography, analytics, proteins, and ligands.
Strategic expansion in Asia, especially China, is a priority, supported by new leadership, OEM deals, and a strategy to capture rapid market growth.
Transformation Office established to accelerate top-line growth and margin improvement, targeting 30% EBITDA margin by 2030 and delivering at least one point of annualized margin benefit by end of 2027.
Digitization and process analytical technologies are central, with plans to integrate digital twins and AI for process optimization.
M&A remains a top capital allocation priority, with recent acquisitions and minority investments supporting growth and innovation.
Financial performance and growth outlook
Achieved $738 million in revenue last year, with FY26 guidance set at $803M–$833M and 9–13% organic growth.
Maintained 16% organic growth last year and 16% organic non-COVID growth in 2025, outpacing industry growth.
Analytics and chromatography franchises projected to grow over 20% in FY26, with analytics up over 50% in Q1.
Targeting mid-teens revenue CAGR through 2030, aiming to double the business primarily via organic growth.
Committed to margin expansion, with a roadmap to ~30% EBITDA margin by 2030, driven by volume leverage, improved mix, and productivity.
Operational initiatives and efficiency
Site rationalization underway, consolidating manufacturing to 8-10 core sites for efficiency and fit-for-growth initiatives.
Service improvements reduced equipment installation time from four months to 1.5 weeks.
Transformation Office also focuses on IT modernization, AI implementation, and operational excellence.
Key account management leverages deep industry relationships to drive sales growth and cross-selling.
Leadership structure strengthened to empower teams and support multi-billion dollar ambitions.
Latest events from Repligen
- $1.5B acquisition accelerates cell therapy leadership, delivers synergies, and targets Q4 2026 close.RGEN
M&A announcement22 Jul 2026 - Innovation and strategic expansion drive optimism for double-digit growth and margin recovery.RGEN
2024 Wells Fargo Healthcare Conference9 Jul 2026 - Strong Q3 growth, minimal US vaccine exposure, and margin expansion expected in 2025.RGEN
Stifel 2024 Healthcare Conference8 Jul 2026 - Q3 2025 saw 22% revenue growth, margin gains, and raised guidance amid global strength.RGEN
Q3 20258 Jul 2026 - Q2 2025 revenue grew 15% with 17% organic non-COVID growth and raised full-year guidance.RGEN
Q2 20258 Jul 2026 - Q3 revenue up 10% to $155M, with strong CDMO growth, improved margins, and pending acquisition.RGEN
Q3 20248 Jul 2026 - Robust growth, margin expansion, and strategic investments position the business for long-term gains.RGEN
UBS Global Healthcare Conference 20258 Jul 2026 - 2024 revenue and orders rebounded, with 2025 guidance targeting double-digit growth and margin gains.RGEN
Q4 20248 Jul 2026 - Strong Q1, raised guidance, and strategic moves position for sustained growth and margin expansion.RGEN
Bank of America Global Healthcare Conference 202619 May 2026